Menu
Menu
Granules India has achieved a significant milestone with USFDA approval for its generic Lisdexamfetamine Dimesylate chewable tablets, providing a more affordable option for treating ADHD and binge eating disorder. This approval addresses critical drug shortages in the U.S. and strengthens Granules’ presence in the global pharmaceutical market.
Granules India’s stock has dropped 13% amid a series of regulatory challenges from the USFDA. The agency's recent inspection of the Gagillapur facility resulted in six significant observations, leading to investor concerns and a sharp decline in share value. This blog delves into the details of the USFDA's findings, Granules India’s response, and the broader implications for the company and its investors. Stay tuned for a comprehensive analysis of this developing story.